Ascendis Pharma Ads (NQ: ASND )

157.03 USD +0.47 (+0.30%)

Streaming Delayed Price Updated: 9:48 AM EDT, Oct 20, 2020 Add to My Watchlist

Price and Volume

Volume	1,066
Open	157.22
Bid (Size)	155.74 (1)
Ask (Size)	158.33 (1)
Prev. Close	156.57
Today's Range	156.97 - 157.22
52wk Range	92.00 - 166.99
Shares Outstanding	41,779,122
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypo

September 28, 2020

Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan

September 23, 2020

Performance

YTD	+11.27%	+11.27%
1 Month	+11.61%	+11.61%
3 Month	+7.72%	+7.72%
6 Month	+13.31%	+13.31%
1 Year	+51.93%	+51.93%

More News

Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020

September 15, 2020

Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

September 11, 2020

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting

September 10, 2020

Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

September 08, 2020

Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)

September 04, 2020

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology

September 04, 2020

Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference

September 02, 2020

Stocks Showing Rising Market Leadership: Ascendis Pharma Earns 82 RS Rating

September 25, 2020

Ascendis Pharma Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

September 24, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.